Abstract

Based on data mining, an innovative big data analysis platform was utilized to discuss the treatment of cancer in chronic myeloid leukemia (CML) by dasatinib, aiming to offer help to the diagnosis and treatment of cancer. An integrated gene expression analysis system (IEAS) was firstly constructed to automatically classify data in the online human Mendelian genetic database using clustering algorithms. At the same time, the gene expression profile was analyzed by principal component analysis (PCA) in the analysis system. In addition, the efficacy of dasatinib in the treatment of patients with advanced CML was then retrospectively analyzed. The results showed that the IEAS system could incorporate the gene expression analysis vectors it contained by JAVA-related technologies, and the generated clustering genes showed similar functions. The clustering algorithm could homogenize data and generate visual clustering heat maps. The analysis results of major elements were diverse under different experimental conditions. The characteristic value of the first major element was the largest. Messenger ribonucleic acid (mRNA) datasets of CML patients were selected from cancer genomic map, including 120 samples and 20,614 mRNA in total. In micro-RNA (miRNA) datasets, there were 202 samples including 1,406 miRNAs. Data were screened by miRNA–mRNA regulation template, and 20 differentially expressed mRNAs were obtained. In conclusion, the proposed IEAS system could mine and analyze the gene expression data. Dasatinib showed good efficacy in the treatment of patients with advanced CML. Besides, it could improve visual queries, and data mining had a broad application prospect in clinical application. Dasatinib was considered to be a good option for patients with advanced CML.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.